Amgen's stock dipped 0.4% to $327.31, highlighting a neutral risk management stance as investors await clearer directional signals in the market. While bullish sentiment persists around healthcare due to perceived regulatory stability and M&A potential, trading is expected to remain rangebound without significant catalysts, indicating this slight profit-taking is likely just normal consolidation rather than a trend reversal.